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Abstract: The study of the reactivity of the enantiopure ferrocenyl Schiff base  
(SC)-[FcCH=N–CH(Me)(C6H5)] (1) (Fc = (η5-C5H5)Fe(η5-C5H4)) with cis-[PtCl2(dmso)2] 
under different experimental conditions is reported. Four different types of chiral Pt(II) 
have been isolated and characterized. One of them is the enantiomerically pure trans-(SC)-
[Pt{κ1-N[FcCH=N–CH(Me)(C6H5)]}Cl2(dmso)] (2a) in which the imine acts as a neutral 
N-donor ligand; while the other three are the cycloplatinated complexes: [Pt{κ2-C,N 
[(C6H4)–N=CHFc]}Cl(dmso)] (7a) and the two diastereomers {(Sp,SC) and (Rp,SC)} of 
[Pt{κ2-C,N[(η5-C5H3)–CH=N–{CH(Me)(C6H5)}]Fe(η5-C5H5)}Cl(dmso)] (8a and 9a, 
respectively). Isomers 7a-9a, differ in the nature of the metallated carbon atom [CPh (in 7a) 
or CFc (in 8a and 9a)] or the planar chirality of the 1,2-disubstituted ferrocenyl unit (8a and 
9a). Reactions of 7a–9a with PPh3 gave [Pt{κ2-C,N[(C6H4)–N=CHFc]}Cl(PPh3)] (in 7b) and 
the diastereomers (Sp,SC) and (Rp,SC) of [Pt{κ2-C,N[(η5-C5H3)–CH=N–{CH(Me)(C6H5)}] 
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Fe(η5-C5H5)}Cl(PPh3)] (8b and 9b, respectively). Comparative studies of the electrochemical 
properties and cytotoxic activities on MCF7 and MDA-MB231 breast cancer cell lines of 2a 
and cycloplatinated complexes 7b-9b are also reported. Theoretical studies based on DFT 
calculations have also been carried out in order to rationalize the results obtained from the 
cycloplatination of 1, the stability of the Pt(II) complexes and their electrochemical properties. 




Cyclometallated platinum (II) complexes containing bidentate (C,N)− or terdentate ((C,N,E)q, 
(N,C,E)q, (E = N, S or O and q = −1 or −2) or (C,N,C')2−) ligands are nowadays one of the most 
attractive type of organoplatinum compounds [1–10]. This is mainly due to their physical, chemical, 
photo-physical and electrochemical properties, or the reactivity of their ground and excited states that 
make them extremely useful in a wide range of fields [1–10]. It is well-known that platinacycles are 
valuable precursors in homogeneous catalysis, as building blocks in supra- and macromolecular 
chemistry as well as for the synthesis of organic compounds (including natural products) and other 
organometallic products (i.e., cyclometallated Pt(IV) derivatives) [11–15]. Sensors, detectors, 
biomarkers, molecular machines (i.e., switches), imaging probes and different sorts of OLEDs 
(including white and white polymer light-emitting diodes (WOLED and PGOLED), respectively) 
containing cycloplatinated cores have been described [16–25]. Furthermore, cyclometallated Pt(II) 
complexes with antitumoral activity have been known for a long time, but the idea of using this sort of 
products in drug discovery is becoming more and more popular [15,26–33]. For illustrative purposes 
recent examples of platinacycles with bidentate (CPh, N)− ligands showing greater cytotoxic activity 
than cisplatin are shown in Figure 1 [29,32,33]. 
Figure 1. A selection of cyclometallated Pt(II) complexes with a σ(Pt-CPh) bond and  
potent cytotoxic activity reported recently. For illustrative purposes IC50 values (in µM) for 
A–C in a specific cancer cell line are given: in HCT-116 colon cell line for A compounds: 
IC50 = 28 ± 2.4 µM (R1 = H) and 18 ± 1.9 µM (R1 = Cl); for type B, IC50 in the range  
0.95 µM–7.7 µM (IC50 for cisplatin = 40 ± 4.4 µM). Compound C was tested in the A549 





















R1 = H or Cl R2 = Me, H, F and  R3 = Cl, H, F  
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It is well-known that the properties of cycloplatinated compounds, their biological or catalytical 
activities and their applications are strongly dependent on a wide variety of factors, such as the nature 
of the donor atoms of the metallated ligand, its denticity, the size of the metallacycle, the electronic 
and steric effects induced by the presence of substituents and their location and even the nature of the 
ancillary ligands and their relative arrangement [1–10]. 
On the other hand, N-donor ferrocenyl ligands are valuable reagents to achieve heterodimetallic  
Pt (II) compounds [34–43]. These ligands may produce different types of products depending on the 
relative arrangement between the N-donor atom and the presence of: (a) one or more σ(C–H) bonds, 
with the proper orientation as to undergo metallation, and/or (b) additional heteroatoms with good 
donor abilities and their location [36,37,40,41]. Moreover, for monosubtituted ferrocene derivatives 
metallation of the C5H4 ring induces planar quirality [34,35,38]. Despite the variety of cyclometallated 
Pt(II) complexes derived from achiral N-donor ligands described so far, enantio- or diastereomerically 
pure platinacycles are scarce [39–47] and those containing a Pt–CFc bond are even less common [39–43]. 
However, the examples described so far are especially outstanding because of their singular properties, 
behaviors or activities [39–43]. A few representative examples (A–D) are shown in Figure 2. 
Compound A is an excellent catalyst on the asymmetric aza-Claisen rearrangement of Z configured 
trifuoroacetaamidates giving high enantioselectivities [39] and diastereomers B and C (Figure 2), form 
an acid-base dependent chiral molecular switch [40,41]. Platinacycles D and E are potent cytotoxic 
agents in lung (A549), breast (MDA-MB231) and colon (HCT-116) cell lines. Moreover, complex E: 
(a) is less toxic than cisplatin and active in other cancer cell lines (i.e., NCI-H460); (b) induces nuclear 
translocation of endogenous FOXO3a and a FOXO3a reporter protein in A549 and U2OS cells, 
respectively; and (c) has a synergic effect with cisplatin [42,43]. 
Figure 2. Representative examples of diastereomerically pure cyclometallated Pt(II) 

















































All these findings suggest that compounds containing simultaneously ferrocenyl units and 
cycloplatinated rings are promising candidates for the design of multifunctional products with both 
biological activity and interesting electrochemical properties (due to the presence of a redox active 
center). This is still an emerging topic and further work is needed to clarify some key points. 
Unfortunately, isomeric platinacycles differing exclusively in the nature of the metallated carbon have 
not been described so far, and thus the effect produced by the characteristics of the carbon atom bound 
to the Pt(II) (i.e., CFc versus CPh) on their properties and activities still remains unknown.  
Since during the preparation of D and E (Figure 2), no evidences of the formation of platinacycles 
arising from the metallation of the phenyl ring were detected [42], we decided to investigate whether 
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for (SC)-[FcC(H)=N–CH(Me)(C6H5)] (1) (Figure 3) [48], the relative orientation between the phenyl ring 
and the N atom and their proximity could also allow the isolation of platinacycles with a Pt–CPh bond. 
Figure 3. Schiff base 1 selected for this study and schematic view of the different types of 
Pt(II) complexes (2–11) that may be formed. Compounds 2-11 differ in the conformation 
of the ligand (anti-(E) in 2, 4, 6, 8–11 or syn-(Z) in 3, 5 and 7), the binding mode of the  
imine ((N) in 2–5, (C,N)− in 6–9 or (C,N,C')2− in 10 and 11), the type of metallated C  
atom (CPh in 6 and 7 or CFc in 8 and 9), the number of Pt–C bonds contained (one in 6–9  
or two in 10 and 11) or the planar chirality of the Fc unit (Sp in 8 and 10 or Rp in 9 and 11).  












































































2,  trans-, anti-(E), (SC) 3, trans-, syn-(Z), (SC) 4,  cis-, syn-(Z), (SC) 5, cis-, syn- (Z), (SC)
6, anti-(E), (SC) 7, syn-(Z), (SC) 8, anti-(E),(Sp,SC) 9, anti-(E),(Rp SC)
10, anti-(E),(Sp,SC) 11, anti-(E), (Rp,SC)  
Ligand 1 may exhibit different binding modes and hapticities giving a wide variety of Pt(II) 
complexes (Figure 3). If 1 binds to the Pt(II) atom through the imine nitrogen exclusively, different 
isomeric forms of the optically active complexes: [Pt{κ1-N[FcC(H)=N–CH(Me)(C6H5)]}X2(L)] could 
be expected (2–4 in Figure 3). They differ in the anti-(E) (in 2 and 3) or the syn-(Z) (in 4 and 5) form 
of the imine and a trans- (in 2 and 4) or cis- (in 3 and 4) disposition of the X− ligands. Moreover, 1 has 
several carbon atoms susceptible to undergo metallation. Four types of platinacycles (Figure 3, 6–9) 
could arise from monometallation of 1. In two of them (6 and 7) there is a σ(Pt–CPh) bond, and the 
imine adopts the anti-(E) (in 6) or syn-(Z) (in 7) forms; while the other two (8 and 9) are diastereomers 
(Sp,SC) and (Rp,SC) arising from platination of the C5H3 ring that induces planar chirality [34,35,38]. 
A few examples of cyclometallated Pt(II) compounds with (C,N,C)2− pincer ligands have been 
reported [49–52], and thus the activation of a σ(CPh–H] and a σ(CFc–H] bond to give compounds 10 or 11 
(Figure 3) cannot be disregarded. Furthermore, and since several groups have achieved cylometallated 
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Pt(IV) complexes in the reaction of cis-[PtCl2(dmso)2] with N-donor ligands [23,53,54], the formation 
of the platinum(IV) derivatives cannot be ruled out either. 
In this work, we report: (a) the synthesis of chiral Pt(II) complexes in which 1 adopts different binding 
modes {(N), (CFc, N)− or (CPh, N)−}, (b) a comparative study of their electrochemical and cytotoxic 
activities in two breast cancer cell lines, and (c) a theoretical study based on DFT calculations to explain the 
selectivity of the metallation process and the properties of the new Pt(II) compounds. 
2. Results and Discussion 
2.1. Synthesis and Characterization of the Compounds 
Treatment of equimolar amounts of (SC)-[FcC(H)=N–CH(Me)(C6H5)] (1) and cis-[PtCl2(dmso)2] 
under reflux for 2 h, followed by work up of a SiO2 column chromatography, gave traces of 
ferrocenecarboxaldehyde (FcCHO, 12 mg) and two new Pt(II) compounds in a molar ratio 1.00:0.13 
(Scheme 1, step A). 
Scheme 1. Synthesis of the new Pt(II) complexes: (i) cis-[PtCl2(dmso)2] in refluxing 
MeOH (2 h) followed by SiO2 column chromatography; (ii) cis-[PtCl2(dmso)2] and NaOAc 
in a toluene:MeOH (4:1) mixture {molar ratios 1:Pt(II):OAc− = 1:1:2} under reflux (see 
text) followed by SiO2 chromatography; (iii) PPh3 in CH2Cl2 under reflux for 1 h; (iv) 






























































Elemental analyses and mass spectra of the major component (Supporting Information) were 
consistent with those expected for any of the four isomers of [Pt(1)Cl2(dmso)] (Figure 3, types 2–5 
with X = Cl and L = dmso (2a–5a)). In the 1H-NMR spectrum the signals due to the protons of the 
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dmso ligand appeared as one singlet at δ = 3.40 ppm (3JH,Pt = 19 Hz). This is characteristic of trans-[Pt 
{κ1-N[FcC(R1)=N–R2]}Cl2(dmso)] (R1 = H or Me) complexes [20,36,40–42]. Moreover, in its (1H–1H) 
NOESY spectrum, the signal of the imine proton showed cross peaks with those of the H2 and H5 
protons of the Fc unit, and also with the resonances of the −CH(Me)-moiety. Thus indicating that 
imine 1 adopts the anti-(E) form. All these features suggested that in the major product the 
arrangement of the ligands corresponded to type 2 shown in Figure 1 (with X = Cl and L = dmso, 
herein after referred to as 2a). 
Its X-ray crystal structure (Figure 4) consists of discrete molecules of trans-[Pt{κ1- 
N[(η5-C5H5)Fe[(η5-C5H4)–CH=N–CH(Me)(C6H5)]}Cl2(dmso)] separated by van der Waals contacts. In 
each molecule, the Pt(II) is bound to the imine nitrogen, the sulphur of the dmso ligand and to the 
Cl(1) and Cl(2) atoms, in a trans- arrangement [bond angle Cl(1)–Pt–Cl(2) = 176.7(1)°], giving a 
slightly distorted square-planar environment around the Pt(II) atom. The Pt-ligands’ bond lengths 
agree with those reported for trans-[Pt(imine)Cl2(dmso)] compounds [20,41,55,56]. 
Figure 4. Molecular structure and atom labelling scheme for trans-(Sc)-[Pt{(η5-C5H5)Fe 
[(η5-C5H4)–CH=N–CH(Me)(C6H5)]Fe(η5-C5H5)}Cl2(dmso)] (2). Selected bond lengths (in 
Å) and angles (in deg.): Pt–N, 2.017(5); Pt–S, 2.206(2); Pt–Cl(1), 2.266(3); Pt–Cl(2), 
2.280(3); C(10)–C(11), 1.424(12); C(11)–N, 1.261(9); N–C(12), 1.481(11); C(12)–C(13), 
1.516(15); C(12)–C(14), 1.532(13); C(14)–C(15), 1.321(15); C(15)–C(16), 1.409(17); 
C(16)–C(17), 1.32(2); C(17)–C(18), 1.45(2); C(18)–C(19), 1.377(19); C(19)–C(14), 
1.404(13); S–O, 1.444(8); S–Pt–Cl(1), 92.82(10); S–Pt–Cl(2) ,90.0(1);N–Pt–Cl(1), 
88.4(2); N–Pt–Cl(2), 88.6(2); C(6)–C(10)–C(11), 118.9(8); C(9)–C(10)–C(11), 132.1(7);  
C(10)–C(11)–N, 128.6(7); C(11)–N–C(12), 116.0(6); N–C(12)–C(13), 111.2(8);  
N–C(12)–C(14), 112.9(8); O–S–C(20), 107.3(7); O–S–C(21), 107.6(6) and C(20)–S–
C(21), 102.7(8). 
 
The imine is in anti-(E) form [torsion angle C(10)–C(11)–N(1)–C(12) = 175.9°] in good agreement 
with the conclusions reached by NMR and the C(10)–N(1) bond length (1.261(9) Å) is similar to that 
reported for [Pd(1)(η3-C3H5)Cl] [1.255(6) Å] [48]. Bond lengths and angles of the Fc moiety are 
similar to those reported for most monosustituted ferrocenes [55,57]; the two pentagonal rings are 
planar, nearly parallel (tilt angle = 2.9°) and they deviate by 10.6(5)° from the ideal eclipsed 
conformation. The Fe(II)···Pt(II) distance (4.748 Å) precludes the existence of any direct interaction. 
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In the crystals, molecules are connected by weak Cl···H intermolecular interactions between: (a) the 
Cl(1) and the H(3) of a close molecule at (1 − x, −1/2 − y, 1/2 − z) (distance Cl(1)···H(3) = 2.894(8) Å) 
and (b) the Cl(2) and the H(15) atoms of another unit located at (1/2 + x, 5/2 − y, −z), (Cl(2)···H(15) = 
2.690(7) Å) forming chains. These chains are connected through additional C(17)−H(17)···O and 
C(21)−H(21)··· π (C(6)−C(10) ring) interactions. 
Elemental analyses and mass spectra of the minor component (I) were consistent with those 
expected for any of the platinacycles with (C,N)− bidentate ligands (types 6–9, in Figure 2 with X = Cl 
and L = dmso (6a–9a)}. In the 1H-NMR spectrum: (a) the resonances of the protons of the dmso 
appeared as a singlet, this is consistent with trans-arrangement of the dmso and imine nitrogen; and (b) 
the signal of the imine proton (at δ = 8.91 ppm, (4JH,Pt = 51 Hz)) was low-field shifted in relation to the 
free ligand (δ = 8.20 ppm) [48]. This suggested, according to the bibliography [20,36,37,40–42], that 1 
adopted the syn-(Z) form. Besides that, only four cross peaks were detected in the aromatic region of 
the {1H–13C}-HSQC spectra, indicating the existence of a Pt−CPh bond in the complex. The 195Pt 
chemical shift was similar to those of complexes with “Pt(CPh ,N)ClS(dmso)” cores. All these findings 
indicate that I was [Pt{κ2-C,N-[(C6H4)−CH(Me)−N=C(H)Fc]}Cl(dmso)] (Figure 3, type 7, with X = Cl 
and L = dmso (7a)). Moreover, since it has been demonstrated that cyclometallation of enantio- or 
diastereomerically pure N-donor ferrocenyl ligands does not modify the chirality of the stereogenic 
center [40–42,58–60], the absolute configuration of 7a is SC. 
It should be noted that: (a) the molar ratio 2a:7a did not vary significantly when the reaction period 
(t) increased from 2 h (1.00:0.13) to 2 days (1.00:0.15), and (b) no evidences of the presence of 
platinacycles with σ[Pt−C(ferrocenyl)] bonds were detected by 1H-NMR of the crude of the reactions. 
In view of these and since the formation of platinacycles with bidentate (CPh or CFc, N)]− ligands 
commonly requires the presence of a base (i.e., NaOAc or the ligand itself), [20,36,37,40–42], we also 
studied the reactivity of 1 toward Pt(II) in the presence of NaOAc. 
Treatment of ligand 1 with cis-[PtCl2(dmso)2] and NaAcO (in a molar ratio 1:Pt(II):OAc− = (1:1:2)) 
in a mixture of toluene: MeOH (4:1) under reflux for 2 h (Scheme 1, step B) followed by the work-up 
of a chromatographic column, gave small amounts of FcCHO (18 mg), compounds 2a, 7a and traces 
(ca. 9 mg) of a purple solid (hereinafter referred to as II). Elemental analyses of II agreed with those 
expected for the platinacycles with 1 acting as a (C,N)− ligand. Its 1H-NMR spectrum showed two sets of 
superimposed signals (of relative intensities 1.00:0.90) with the typical pattern of 1,2-disubstituted 
ferrocene derivatives. Thus, indicating the presence of two species with a Pt−CFc bond in solution. Since 
metallation of the C5H4 ring induces planar chirality [20,38,40–42,58–60], two diastereomers ((Sp, SC) and 
(Rp,SC)) could be expected in principle (Figure 3, types 8 and 9 with X = Cl and L = dmso (8a and 9a, 
respectively)). Consequently II contains a mixture of both isomers. Longer reaction periods (up to 6 days) 
produced significant variations of the relative abundance of 2a, 7a and II, (from 1.00:0.21:0.09 (for t = 2 h) 
to 1.00:0.46:0.64 (for t = 2 days)); and after 6 days, the typical resonances of 2a were not detected in the 
1H-NMR spectrum of the crude of the reaction and only FcCHO, 7a and II were isolated after the work 
up of the column. These results suggested that the formation of isomers (8a and 9a) was slow. 
Since: (a) the crystal structure of 2a revealed that the C−H bond of the ferrocenyl unit is quite close 
to the Pt(II) ion (distance Pt···H(9) = 2.866 Å); and (b) the relative proportion 2a: II decreased with 
time; we tentatively assumed that probably 2a was the precursor of the mixture II. In order to test this 
hypothesis, compound 2a was treated with NaOAc (in a 1:2 molar ratio) in toluene:MeOH (4:1) under 
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reflux for 6 days and then filtered and concentrated to dryness. NMR studies revealed the presence of 
FcCHO and the two diastereomers of II in a relative ratio (1.00:0.86) which is close to that obtained 
when the reaction was performed using ligand 1, cis-[PtCl2(dmso)2] and NaAcO (1.00:0.90). 
All the results presented here reveal that despite it is well-known that ferrocene derivatives are more 
prone to undergo electrophilic attacks than their phenyl analogues [34,35,58,61], for 1, that has 
different types of σ(C−H) bonds susceptible to metallate, the formation of the platinacycle 7a with a 
σ[Pt−C(phenyl)] is achieved under milder experimental conditions than those required to isolate the 8a 
and 9a with a σ[Pt−C(ferrocenyl)] bond. Unfortunately, attempts to separate the two components of II 
by fractional crystallisation or SiO2 column chromatography failed and only solids enriched in ca.  
70%–80% could be isolated by successive chromatographic columns. 
Since it is well-known that platinacycles with PPh3 ligands are more cytotoxic than their dmso 
analogues, we decided to study the reactivity of the platinacycles with PPh3. As expected, treatment of 
II with the equimolar amount of PPh3 gave the diastereomers (Rp, SC) and (Sp, SC) of [Pt{{κ2-C,N- 
[(η5-C5H3)−CH=N−CH(Me)(C6H4)]Fe(η5-C5H5)}Cl(PPh3)] (8b and 9b, respectively) that could be isolated 
after a careful work-up of a SiO2 column (Scheme 1, step C). In order to compare the electrochemical 
properties and the cytotoxic activities of isomeric compounds differing only in the nature of the metallated 
carbon, we also transformed platinacycle 7a in CH2Cl2 following identical procedure and we isolated the 
(SC)-[Pt{κ2-C,N-[(C6H4)−CH(Me)−N=C(H)Fc}Cl(PPh3)] (7b) (Scheme 1, step D). 
Characterization data of 7b–9b (Supplementary Information) agreed with the proposed formulae. 
31P{1H}-NMR data for 7b (δ = 19.1 (1JPt−P = 3801 Hz)), 8b (δ = 15.9 (1JPt−P= 4191 Hz)) and 9b (δ = 
15.7 (1JPt−P = 4202 Hz)) are similar to those reported for related platinacycles with “(CPh or CFc, 
N,P,Cl)” cores and a trans- arrangement of the PPh3 ligand and the imine nitrogen in good agreement 
with the transphobia effect [61]. 195Pt NMR spectra of compounds 7b–9b showed a doublet due to 
coupling with the 31P-nucleus since it is well-known that an upfield shift in 195Pt NMR is related to a 
strong donor interaction [62,63], Thus, differences detected in the 195Pt chemical shifts of 7b and those 
of 8b and 9b can be taken as a measure of the different donor abilities of imine 1 adopting the (CPh,N)− 
or the (CFc,N)− binding mode. 
At this point and due to the increasing interest in platinacycles with (C,N,C')2− pincer ligands we 
turned our attention to 8b and 9b. Molecular models revealed that in both isomers the C−H bond on 
the ortho site of the phenyl ring has the proper orientation as undergo metallation to give platinacycles  
with 1 acting as a (CFc,N, CPh)2− pincer ligand (Figure 2, types 10 and 11 with X = Cl and L = PPh3 
(10b and 11b)) and having central and planar chirality. In view of this, we also studied the reactions of 
the 8b (or 9b) with equimolar amounts of a NaOAc under reflux for 2 days in the toluene: MeOH (4:1) 
mixtures. However, no significant change was observed and 1H-NMR spectra of the raw materials did 
not reveal the presence of any new Pt(II) complex. 
As mentioned above, isomeric cycloplatinated complexes differing exclusively in the nature of the 
metallated carbon or the planar chirality of the metallated ferrocenyl moiety are scarce and studies on 
chiral derivatives are even less common. In view of this and mainly due to the ongoing interest in: (a) 
the potential antitumoral activity of platinacycles [1,15,26–32,42–43] and (b) electrochemical 
properties of ferrocene derivatives and heteropolymetallic complexes with ferrocenyl ligands 
[34,35,40,41,59], we decided to use compounds 7b–9b for preliminary studies on these fields. 
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2.2. Study of the Cytotoxic Activity 
Two human breast cancer cell lines (MCF7 and MDA-MB231) were used to test the cytotoxic 
activity of complex 2a and the platinacycles (7b–9b). For comparison purposes, cisplatin (as positive 
control) was also evaluated under the same experimental conditions. The IC50 values corresponding to 
the inhibition of cancer cell growth at 50% level are listed in Table 1. 
Table 1. Summary of: (a) the cytotoxic activities (IC50 (µM)) of compound 2a and the 
platinacycles 7b–9b in the MCF7 and MDA-MB231 breast cancer cell lines a; and (b) their 
electrochemical properties (Electrochemical data (anodic (Epa) and cathodic (Epc) 
potentials, separation between peaks (ΔE = Epa – Epc) and the ratio between the intensities 




Cytotoxic activity, IC50 Electrochemical data 
MCF7 MDA-MB231 Epa Epc ΔE Ipa/Ipc 
2a N >100 76 ± nd 0.076 0.006 0.070 1.08 
7b (CPh, N)− 37 ± 4 29 ± 3 0.101 0.038 0.063 1.10 
8b (CFc, N)− 11.4 ± 1.1 5.8 ± 0.8 −0.127 −0.197 0.070 0.98 
9b (CFc, N)− 9.2 ± 0.9 4.3 ± 0.6 −0.157 −0.228 0.071 0.97 
a IC50 values for cisplatin under identical experimental conditions = 19.4 ± 4.5 µM (in MCF7) and 6.3 ± 2.4 µM 
(in MDA-MB231); b Potentials (in V) are referred to the ferrocene/ferricinium couple. 
The comparison of in vitro cytotoxic activities of 2a, 7b, 8b and 9b against the MCF7 and  
MDA-MB231 breast cancer cell lines (Table 1 and Figure 5a) shows that complex 2a, where 1 acts as 
an N-donor group, did not show any significant effect on the MCF7 cell line and only a moderate 
activity in MDA-MB231 cell line and platinacycles 7b–9b were more potent than 2a in the two cell 
lines assayed. In fact, their potencies increase according to sequence (1). 
2a < 7b < cisplatin < 8b ≤ 9b (for MCF7 and MDA-MB231) (1) 
Figure 5. (a) Comparative plot of the cytotoxic activities (IC50 values (µM)) of complexes 
2a, the platinacycles 7b–9b and cisplatin in the MCF7 and MDA-MB231 breast cancer cell 
lines and (b) cyclic voltammograms (at a scan rate of 0.1 V × s−1) of the new Pt(II) 
complexes containing the aldimine 1 acting as a neutral N-donor (in 2a) or as a 
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Among the tested compounds, complex 2a is a weaker cytotoxic agent than 7b; while platinacycle 
9b, (and in a lesser extent, 8b) are the most potent ones (IC50 in the ranges: 9–11 µM for MCF7 and  
5.8–6.3 µM for the triple negative (ER, PR and no HER2 over expression) MDA-MB231 cell line). In 
particular, in particular the activity of 9b is ca. 1.3 times (in MDA-MB231) or 2.1 times (in the MCF7) 
bigger than that of cisplatin. These findings indicate that platinacycles with Pt–CFc bond (8b and 9b) 
are more active than 7b, where the Pt(II) ion is bound to a CPh atom. The cytotoxic activity of the two 
diastereomers (8b and 9b) is a bit different, if significant. This agrees with results obtained for 
compounds D and E (Figure 2) and suggest that the planar quirality of the metallated ring is not as 
important as the type of metallated carbon. Some authors have also found that for substituted ferrocene 
derivatives with stereogenic carbon atoms and their transition metal complexes, the absolute 
configuration does not affect significantly their cytotoxic activity [64–66]. 
Taking into account these results, trend (1) can be re-written as  
(N) < (CPh, N)− < (CFc, N)− (2) 
that is a relationship between binding mode of 1 to the Pt(II) and the cytotoxic activity of the complexes. 
2.3. Electrochemical Properties 
In a first attempt to elucidate the effects produced by the mode of binding of the Schiff base to the 
Pt(II) atoms, and the nature of the metallated carbon atom on the electronic environment of the iron 
(II), we also studied the electrochemical properties of 2a,7b, 8b and 9b. It should be noted that  
1H-NMR spectra of these products in CD3CN revealed they were stable in this solvent. The 
electrochemical studies were carried out by cyclic voltammetry of freshly prepared solutions (10−3 M) 
in acetonitrile using (Bu4N)[PF6] as supporting electrolyte. All these experiments were carried out at 
different scan rates υ (υ = from 0.05 to 1.0 V × s−1). A summary of the electrochemical data for all the 
compounds under study is presented in Table 1. 
The cyclic voltammograms (CVs) (Figure 5b) exhibited one anodic peak with a directly associated 
reduction in the reverse scan, intensities ratio Ipa/Ipc was close to 1.0 and the relationship between the 
Ipa and υ½ was lineal. These findings are consistent with those expected for a simple reversible  
one-electron process [67]. The main difference between the CVs of 2a,7b,8b and 9b is the position of 
the waves, that shift to the anodic region as follows:  
9b < 8b < < 2a < 7b (3) 
For the platinacycles 7b–9b the trend is similar to that obtained for cyclopalladated compounds arising 
from the metallation of the Ph ring or the Fc unit of (1SC,2RC)-[(η5-C5H5)Fe{(η5-C5H4)−CH=N −CH(Me)-
CH(OH)(C6H5)}] [59]. For the diastereomers 8b and 9b, the differences are small and fall in the ranges 
reported for the pairs of isomers (Sp,SC) and (Rp,SC) of [Pt{κ2-C,N[(η5-C5H3)−CH=N 
−CH(R)−CH2(OH)]Fe(η5-C5H5)}Cl(PPh3)] (R = Me or iPr) or (Sp,1SC,2RC) and (Rp,1SC,2RC) of [Pt{κ2-
C,N[(η5-C5H3)−CH=N−CH(Me)−CH(OH)(C6H5)]Fe(η5-C5H5)}Cl(PPh3)] [40,41,59]. 
It is well-known that the proclivity of ferrocene derivatives to oxidize is strongly dependent on the 
nature of the substituents [41,59,61,67,68]. In general, the presence of electron withdrawing groups 
produces an increase of the Epa value; while donor groups have the opposite effect. On these basis, 
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sequence (4) provides conclusive evidences of the influence of the binding mode of the ligand 1 to the 
Pt(II) on their the electrochemical properties of the complexes. 
Compounds 8b and 9b with the (CFc,N)− ligand are more prone to oxidize than 2a where 1 binds to 
the Pt(II) through the N atom exclusively; while platinacycle 7b is even more resistant to oxidation. 
Thus indicating that in 7b the metallacycle has greater electron pulling effect on the ferrocenyl array 
than in 8b, 9b. Comparison of electrochemical data of platinacycles 7b–9b and their biological 
activity, reveals that 7b is simultaneously less prone to oxidize and a weaker cytotoxic agent than 8b 
and 9b. This relation shift has also been found for other ferrocene-containing compounds [69,70]. 
2.4. Theoretical Studies 
In a first attempt to rationalise the experimental results and in particular, to explain: (a) why for 1 
the cycloplatination of the phenyl ring occurs; and (b) the electrochemical properties of the Pt(II) 
complexes, we decided to undertake DFT calculations of the imine 1 [in the anti-(E) and syn-(Z) 
forms, herein after referred to as 1E and 1Z, respectively], the isomers of [Pt{FcC(H)=CH(Me) 
(C6H5)}Cl2(dmso)] (2a and 3a) and platinacycles 6–9 of Figure 2 (X = Cl and L = dmso (6a–9a)). 
All the calculations were carried out using the B3LYP hybrid functional [70,71] and the LANL2DZ 
basis set [72,73] implemented in the Gaussian03 program [74]. The geometries of compounds and 
were optimized without imposing any restriction. The bond lengths and angles of the optimized 
geometry of 2a were consistent with those obtained from the X-ray studies (the differences did not 
clearly exceed 3σ).  
For each one of the molecules under study in their optimized geometries the total energy (ET) was 
calculated. The results obtained showed that the free ligand in the syn-(Z) conformation (1Z) is 5.29 
kcal/mol higher in energy than the anti-(E) isomer (1E). Thus, suggesting that the energy required for 
the process 1E → 1Z (Scheme 2, step A) is expected to be small, but slightly greater than for the  
anti-(E)→syn-(Z) isomerization of the ligand in trans-[Pt{FcC(H)=CH(Me)−(C6H5)]}Cl2(dmso)] (2a) 
(Scheme 2, B). 
Complex 2a has several sites susceptible to metallate which would produce either 6a (Scheme 2,  
step C) or the isomers 8a and 9a (Scheme 2, steps D and E); but for 3a only the metallation of the 
phenyl ring, to give 7a, is possible (Scheme 2, step F). In steps C–F the formation of the platinacycles 
requires the release of one of the Cl− ligands and the activation of the corresponding σ(C−H) bond. On 
the other hand, the experimental work shows that despite the Fc unit is more prone to undergo 
electrophillic attacks than the phenyl ring [22], the formation of 7a is achieved under milder 
experimental conditions than for 8a and 9a. 
As a first approach to rationalize experimental results, first we determined the energy for the 
optimized geometries of 6a–9a. The minimum value was obtained for 9a; for 8a, it was only 0.71 
kcal/mol higher; but for 7a and 6a the calculated energies exceed, (by 4.05 and 16.42 kcal/mol, 
respectively), that obtained for 9a. 
We also calculated the energy variations for reactions C–F, where complex 2a is transformed into 
the platinacycles 6a, 8a and 9a; or 3a into 7a. These processes involve the activation of the C–H bonds 
and the formation of the monocycloplatinated products. Data presented in Scheme 2, indicate that from 
an energetic point of view: (a) for 2a, metallation of the ferrrocenyl moiety to give 8a and 9a is 
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preferred over platination of the phenyl ring; and (b) the reaction 3a → 7a, requires a smaller energy 
income than steps C, D and E. 
Scheme 2. Summary of the different processes studied by DFT calculations that involve:  
(a) the anti-(E) → syn-(Z) isomerization of the free ligand (1) or of compound 2a (steps A 
and B, respectively); (b) the transformation of complex 2a into platinacycles 6a, 8a and 9a 
by activation of the σ(CPh−H) (step C) or the σ(CPh−H) bonds (steps D and E); (c) the 
conversion of complex 3a into the platinacycle 7a (step F) and d) the platination of the 
phenyl ring of 8a or 9a (steps G and H, respectively) to give the biscycloplatinated 
derivatives 10a and 11a. (The values below or next to the arrows are the variations of 
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Using the ET values for isomers 6a–9a and T = 298 K, we also calculated the Boltzmann’s 
distribution to estimate the relative proportion of the four isomers: 51.3 (for 8a), 38.6 (for 9a), 10.0 
(for 7a) and 0.1% (for 6a). Except for 6a, that was neither isolated nor detected in any of the reactions 
studied, the relative amounts of the isomers 7a–9a formed when the reaction was performed using  
cis-[PtCl2(dmso)2], the ligand 1 and NaOAc (in a 1:1:2 molar ratio) follow the trend 7a << 9a < 8a that 
is in good agreement with the results reached from the Boltzman’s analyses. 
Experimental work revealed that 2a could be converted into 8a and 9a, but this process required the 
presence of a two fold excess of NaOAc and long refluxing periods (6 days). However, attempts to 
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achieve platinacycles with 1 acting as (CFc,N,CPh)2− from 8a or 9a failed. ΔET calculated for steps G and H 
of Scheme 2 is high (more than 2.7 times the ΔET of D or of E). This may explain why no evidences of the 
formation of compounds 10a or 11a were detected in any of the reactions investigated. 
On the other hand, experimental results indicate the nature of the C atom bound to the Pt(II) in 
platinacycles 7b–9b produces great changes in their electrochemical properties. Since the oxidation 
requires the removal of the electron from the highest occupied molecular orbital (HOMO), molecular 
orbital calculations were also performed for platinacycles 7a–9a, for comparison purposes we also 
included complex 6a in these calculations. 
For 6a and 7a, the HOMO (Figure 6), is mainly formed by the contribution of a 5d orbital of the 
Pt(II), a 3p orbital of the chloride, and a π orbital of the metallated phenyl ring. The HOMOs of 8a and 
9a are markedly different since they are mainly centered on the Fe(II) and the Pt(II) atoms. These 
findings confirm that for 6a–9a the HOMO is not only iron based. For 6a–9a LUMO orbitals (Figure 6) 
have a similar shape that results from the contribution of a π* orbital of the >C=N− group and to a 
lesser extent an atomic orbital of the Fe(II). 
Figure 6. Highest occupied molecular orbital (HOMO) and LUMO orbitals for the 
cycloplatinated compounds 6a–9a. 
 
In order to explain the different proclivity of compounds 7b–9b to undergo oxidation, we 
determined the energy of the HOMO (EHOMO). As shown in Table 2 EHOMO increases according to the 
sequence 6a ≈ 7a << 8a ≤ 9a, indicating that platinacycles 6a and 7a, with the (CPh, N)− ligand, are 
less prone to oxidize than their analogues formed by metallation of the Fc unit. This trend agrees with 
the results obtained from CV that revealed that 7b less more prone to oxidize than 8b or 9b. 
Table 2. Calculated energies (in hartrees) of the HOMO and LUMO (EHOMO and ELUMO, 
respectively) and energy gap (ELUMO–EHOMO) for the isomers 6a–9a (shown in Scheme 2). 
Compound Binding Mode of 1 EHOMO ELUMO ELUMO–EHOMO 
6a (CPh, N)− −0.204 −0.058 0.146 
7a (CPh, N)− −0.204 −0.062 0.142 
8a (CFc, N)− −0.198 −0.054 0.144 
9a (CFc, N)− −0.193 −0.057 0.136 
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3. Experimental Section 
3.1. Preparation of the Compounds 
3.1.1. trans-(SC)-[Pt{κ1-N[FcC(H)=N−CH(Me)(C6H5)]}Cl2(dmso)] (2a) 
A suspension containing 250 mg (5.92 × 10−4 mol) of cis-[PtCl2(dmso)2] and 40 mL of MeOH 
(HPLC-grade) was refluxed until complete dissolution of the Pt(II) complex. Then, the hot solution 
was filtered out and filtrate was treated with 188 mg (5.92 × 10−4 mol) of ligand 1. The reaction 
mixture was protected from the light with aluminium foil and refluxed for 2 h. After this period the 
solution was concentrated to dryness on a rotary evaporator, Afterwards the residue was dissolved in 
the minimum amont of CH2Cl2 and passed through a SiO2-column chromatography (13.5 cm × 2.3 cm) 
using CH2Cl2 as eluant. The first band collected gave, after concentration to dryness small amounts of 
FcCHO (18 mg). Once this band was collected the subsequent elution with CH2Cl2 produced the 
release of an adidional and wide band, that contained complex 2a. This band was collected and 
concentrated to ca. 5 mL. Slow evaporation of the solvent at 282 K produced the formation of small 
crystals of 2a that were collected and air-dried. (yield: 275 mg, 70.2%). 
3.1.2. (SC)-[Pt{κ2-C,N[(C6H4)(Me)CHN=C(H)Fc]}Cl(dmso)] (7a) 
This compound was obtained as a minor side-product during the preparation of 2a. and it was 
isolated from the column described in the preceding paragraph as follows. After the elution of the band 
containing 2a, the column was eluted with a CH2Cl2: MeOH (100:0.5) mixture. This produced the 
release of a tiny and narrow band that was collected and concentrated to dryness on a rotary 
evaporator. The solid formed was air-dried and then dried in vacuum for 2 days (yield: 34 mg, 9.3%). 
3.1.3. Synthesis of II {a Mixture of the (Sp, SC) and (Rp, SC) Diastereomers [Pt{κ2-C,N 
[(η5-C5H3)−CH=N−{CH(Me)(C6H5)}]Fe(η5-C5H5)}Cl(dmso)] (8a and 9a, respectively) 
This mixture was obtained by using two alternative procedures (a and b) using either 1 and  
cis-[PtCl2(dmso)2] as starting materials (method a) or complex 2a (method b). 
Method a. Cis-[PtCl2(dmso)2] (250 mg, 5.92 × 10−4 mol) and imine 1 (188 mg, 5.92 × 10−4 mol) 
were treated with 40 mL of toluene. Afterwards, a solution formed by NaOAc (98 mg, 1.19 × 10−3 mol) 
and 10 mL of MeOH was added. The reaction mixture weas protected from the light with aluminum foil 
and refluxed for 6 days. After this period, the hot solution was filtered out and the filtrate was concentrated 
to dryness on a rotary evaporator. The residue was kept in a SiO2 dissicator overnight. Then it was 
dissolved in the minimum amount of CH2Cl2 (ca. 10 mL) and passed through a SiO2-column 
chromatography (13.5 cm × 2.3 cm) using CH2Cl2 as eluant. Concentration to dryness of the yellowish 
band eluted gave small amounts of FcCHO (22 mg). Then elution with a CH2Cl2: MeOH (100:0.5) 
mixture, produced two bands of which the first eluted one gave after evaporation of the solvent 
complex 7a (42 mg). The second band that was purple and remained on the top of the column was later 
on collected increasing the polarity of the eluant to 100:1. The solid II, containing the two 
diastereomers (8a and 9a, in a molar ratio 1.00:0.89), was isolated after concentration and the 
subsequent drying in vacuum for 2 days (140 mg). 
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Method b. Compound 2a (120 mg, 1.8 × 10−4 mol) was dissolved in 20 mL of toluene, then a 
solution formed by 30 mg of NaOAc (3.6 × 10−4 mol) and 5 mL of MeOH was added. Then the flask 
containing the reaction mixture was protected from the light with aluminum foil and refluxed for  
6 days. After this period, the nearly black solution was filtered through a Celite pad and the filtrate was 
concentrated to dryness on a rotary evaporator. The purple solid formed, that contained 8a and 9a 
(1.00:0.86), was washed with (3 × 5 mL portions) of n-hexane, air-dried and then dried in vacuum for 
2 days (75 mg, 66%). 
3.1.4. (SC)-[Pt{κ2-C,N[(C6H4)CH(Me)−N=C(H)Fc]}Cl(PPh3)] (7b) 
Complex 7a (21 mg, 3.4 × 10−5 mol) was dissolved in 15 mL of CH2Cl2, then, PPh3 (9 mg,  
3.4 × 10−4 mol) was added. The reaction mixture was protected from the light with aluminum foil and 
refluxed for 1 h. After this period, the undisolved materials were removed by filtration and the pale 
orange filtrate was concentrated on a rotary evaporator to ca. 5 mL. The container was kept overnight 
on a refrigerator. After this period the solution was passed through a fast and short SiO2 column  
(1.0 cm × 0.5 cm) using CH2Cl2 as eluant. The orange band released was collected and concentrated to 
dryness on a rotary evaporator. The solid formed was collected, air-dried and afterwards dried in 
vacuum for 2 days (yield: 27 mg, 69%). 
3.1.5. Preparation of the Mixture of the Diastereomers of [Pt{κ2-C,N[(η5C5H3)−CH=N−CH(Me) 
(C6H5)]Fe(η5-C5H5)}Cl(PPh3)] (8b and 9b) 
To a solution containing 66 mg (1.02 × 10−4 mol) of the mixture of two diastereomers of  
[Pt{κ2-C,N[(η5-C5H3)−CH=N−CH(Me)(C6H5)]Fe(η5-C5H5)}Cl(dmso)] (8a and 9a) and 50 mL of 
CH2Cl2, PPh3 (27 mg, 1.02 × 10−4 mol) was added. The reaction mixture was refluxed for 1 h and then 
filtered out. The filtrate was concentrated to ca. 5 mL and passed through a short SiO2-column 
chromatography. The use of a CH2Cl2:MeOH (100: 0.2) mixture as eluant produced the release of a deep-
orange band which was collected and concentrated to dryness on a rotary evaporator. Finally, the solid was 
dried in vacuum for 3 days and the two diastereomers in a ca 1.0:0.9 molar ratio (58 mg, 70%). 
3.1.6. Separation of the Diastereomers of [Pt{κ2-C,N[(η5-C5H3)−CH=N−CH(Me)(C6H4)] 
Fe(η5-C5H5)}Cl(PPh3)] (8b and 9b) 
A 50 mg amount of the mixture of diastereomers (8b and 9b) was dissolved in the minimum 
amount of CH2Cl2 and passed through a SiO2 column (2.5 cm × 3.0 cm) using a CH2Cl2:MeOH 
(100:0.01) mixture as eluant. The purple band released was collected in ca. 20 mL portions up to a 
total volume of 180 mL and then concentrated to dryness on a rotary evaporator giving 9b (23 mg). 
The solution obtained with the subsequent elution with 160 mL, lead after concentration, a mixture of 
the two isomers; while the final nine fractions collected produced isomer 8b (19 mg). 
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4. Conclusions 
The results presented in this work reveal that the enantiopure imine 1 is a valuable ligand to achieve 
different types of chiral heterodimetallic complexes containing Pt(II) and Fe(II). Among the organic 
compounds that exhibit a similar rich and versatile chemistry in the presence of Pt(II) atoms, ligand 1 
is, to the best of our knowledge, the first that can: (a) generate a variety of chiral complexes with 
ferrocenyl units and (b) adopt three different binding modes ((N) (in 2a), (CPh,N)− (in 7a and 7b) or 
(CPh,N)− (in 8a, 8b, 9a and 9b)), and thus leading to isomeric forms of cyclometallated Pt(II) 
complexes differing in Pt–C bond (CPh (in 7a or 7b) or CFc (in 8a, 8b, 9a and 9b)) or the planar 
chirality {Sp (in 8a and 8b) or Rp (in 9a and 9b)}. It has been reported that cyclopalladation of (1SC, 
2RC) [(η5-C5H5)Fe{(η5-C5H4)−CH=N−CH(R)−CH(OH)(C6H5)}] (R = Me or iPr) gives palladacycles in 
which this imine acts as a (CFc,N)− or (CPh,N)− ligand [59], but for Pt(II) only the diastereomers 
(Sp,1SC,2RC) and (Rp,1SC,2RC) of [Pt{κ2-C,N[(η5-C5H3)−CH=N−CH(Me)−CH(OH)(C6H5)]Fe(η5-
C5H5)}Cl(dmso)] (D and E in Figure 2) were isolated. Thus, indicating that the intercalation of the 
“(RC) –CH(OH)–” unit between the stereogenic carbon of 1 and phenyl ring is important as to hinder 
the formation of platinacycles with a Pt−CPh bond and a [6.6] bicyclic system (the six-membered 
metallacycle fused with the Ph ring). 
Moreover, we have also demonstrated that an accurate control of the experimental conditions 
permits to control the preferential formation of a specific type of product as well as the nature of the 
C−H bond involved in the cycloplatination process. Although the selectivity of the cyclometallation 
process is low, it provides a simple method for achieving enantio- or diastereomerically pure 
organometallic Pt(II) complexes with one stereogenic carbon center and with (in 8a, 8b, 9a and 9b) or 
without (in 2a, 7a and 7b) planar chirality which are extremely scarce, but attracting more and more 
interest due to their potential utilities and applications. 
The new Pt(II) complexes presented herein appear to be excellent candidates for use not only as 
precursors in asymmetric synthesis or catalysis, but also as electrochemical reagents or as cytotoxic 
agents. For instance, an accurate selection of the product allows the fine-tuning of the anodic and 
cathodic potentials in a wide range (i.e., Epa(minimum) = −0.157 V (for 9b) and Epa(maximum) = 0.101 
V (for 7b)). Thus, these compounds are also attractive in view of their potential utility as selective and 
specific electrochemical sensors or detectors. 
Computational studies have also allowed us to explain the effects produced by the nature of  
the metallated carbon atom on the relative stability of platinacycles with “Pt(C,N)(X)(L) cores”  
(Figure 2 6–9), the regioselectivity of the process and also the shift of the waves detected in the  
cyclic voltammograms. 
On the other hand, the biological studies reveal that platinacycle 7b is a weaker cytotoxic agent than 
cisplatin, but 8b and 9b are even more potent agents. This indicates that the binding mode of 1 in the 
platinacycles ((CPh,N)− or (CFc,N)−) is important as to modify their biological activity. Moreover, the 
IC50 values of 8b and 9b in the MDA-MBD231 breast cancer cell line fall in the range obtained for 
compounds D and E (Figure 2), which exhibit a synergic effect with cisplatin [43]. These findings 
open up new research paths mainly focused on the following areas: (a) the evaluation of the cytotoxic 
effect of 8b and 9b in other cancer cell lines including some cisplatin resistant ones, such as HCT-116 
colon cancer cell line; (b) additional studies to bring information about their mechanism of action; (c) 
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the chemical modification of the complexes i.e. by replacement of one or the two ancillary ligands to 
get neutral of ionic derivatives, to be tested on these two breast cancer cell lines. 
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Appendix  
Description of materials and experimental methods used to characterize the compounds and to  
study their properties together with their characterization data (elemental analyses, mass spectra,  
IR-spectrocospic data, and NMR data). The crystallographic file information (cif. file) of compound 2a 
has been deposited at the Cambridge Crystallographic Data Centre (reference code: CCDC-1016768) 
and can be obtained free of charge [75].  
A1. Materials and Methods 
A1.1. General 
Ligand 1 and cis-[PtCl2(dmso)2] were prepared as described previously [48,76]. The success of the 
synthesis of the Pt(II) compounds is strongly dependent on the quality of the methanol used. Methanol 
HPLC-grade is strongly required, because the presence of small amounts of water produces a 
significant decrease of the yields and increases the amount of FcCHO isolated. The remaining solvents 
used in this work were dried and distilled before use [77]. 
Elemental analyses were carried out at the Serveis Cientifico-Tècnics (Univ. Barcelona) and Servei 
de Recursos Cientifics i Tècnics (Univ. Rovira i Virgili, Tarragona). Proton and the two-dimensional 
NMR experiments ((1H-1H)-(COSY) and (NOESY) and the (1H-13C)-(HSQC) and (HMBC)) were run 
at 500MHz with either a Varian 500 or a Bruker (Billerica, MA, USA) Avance 500DMX instruments 
using CDCl3 (99.9%) and SiMe4 as reference). In order to test the stability of the complexes used in 
the electrochemical studies (2a, 7b, 8b and 9b), their 1H-NMR spectra were also registered in CD3CN 
(99.8%) at 298 K. 
195Pt{1H}- (of 7a,b–9a,b) and 31P{1H} (of 7b–9b) NMR spectra were recorded with a  
Bruker-250DXR (Billerica, MA, USA)  instrument using CDCl3 (99.9%) as solvent. The references 
were P(OMe)3 and H2[PtCl6] [δ31P{P(OMe3)} = 140.17 ppm and δ195Pt{H2[PtCl6]} = 0 ppm], 
respectively. In all cases the chemical shifts (δ) are given in ppm and the coupling constants (J) in Hz. 
The optical rotations of 2a, 7b–9b were determined in CH2Cl2 at 298 K using a Perkin Elmer 241 MC 
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polarimeter and the concentration is specified in the characterisation section of the corresponding 
compound. Mass spectra (FAB+) were obtained with a VG-Quatro Fisions instrument using  
3-nitrobenzylalcohol (NBA) as matrix. 
Table A1. Crystal data and structure refinement for trans-(SC)-[Pt{κ1-,N[FcC(H)=N–CH 
(Me)–(C6H5)]}Cl2(dmso)] (2a). 
Structural Parameter  Compound 2a 
Crystal dimmensions/mm × mm × mm 0.2 × 0.1 × 0.1 
Empirical formula C21H25Cl2FeNO2Pt 
Formula weight 661.32 
T/K 293(2) 
λ/Å 0.71073 
Crystal system Orthorhombic 




α = β = γ/° 90.0 
Volume/Å3 2202.6(3) 
Z 4 
Calculated density/Mg × m−3 1.994 
µ/mm−1 7.353 
F(000) 1280 
Θ range for data collection/° 2.06 to 31.72 
Limiting indices 0 ≤ h ≤ 16, −19 ≤ k ≤ 19, −21 ≤ l ≤ 21 
Reflections collected/unique 9069/6010 [R(int) = 0.0705] 
Completeness to Θ = 28.34° 95.2% 
Absorption correction Empirical 
Max. and min. Transmission 0.48 and 0.42 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 6010/0/254 
Goodness-of-fit on F2 1.196 
Final R indices [I > 2σ(I)] R1 = 0.0418, wR2 = 0.1301 
R indices (all data) R1 = 0.514, wR2 = 0.1414 
Absolute struture parameter 0.00(2) 
Largest diff. peak and hole/e Å−3 1.522 and −1.764 
A1.2. Crystallography 
A prismatic crystal of trans-[Pt{κ1-N[FcC(H)=N–CH(Me)(C6H5)]}Cl2(dmso)] (2a) (Table A1) was 
selected and mounted on a MAR345 diffractometer with a image plate detector. Unit-cell parameters 
were determined from 15,901 reflections in the range 3° ≤ Θ ≤ 31° and refined by least-squares 
method. Intensities were collected with a graphite monochromatised Mo-Kα radiation. The number of 
reflections measured in the range was 14,219 of which 6,010 were non-equivalent by symmetry 
(Rint(on I) = 0.0031) and 5106 reflections were assumed as observed applying the condiction I > 2σ(I). 
Lorentz-polarisation and absorption corrections were made. The structure was solved by Direct 
methods using SHELXS computer program [78] and refined by full-matrix least-squares equation 
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using The SHELX97 computer program [79] using 6010 reflections (very negative intensities were not 
assumed). The function minimised was Σ w ││Fo│2 − │Fc│2│ where w = [σ2(I) + (0.0654P)2 + 
4.8984P]−1 and P = (│Fo│2 + 2│Fc│2)/3, were taken from the literature [80]. The chirality of the 
structure was determined from the Flack coefficient [81] which is equal to 0.00(2) for the given results. 
All hydrogen atoms were computed and refined using a riding model, with an isotropic temperature 
factor equal to 1.2 times the equivalent temparature factor of the atom linked to it. The final R factors 
as well as other relevant parameters concerning the resolution and refinement of the crystal structure 
are presented in Table A1. 
A1.3. Biological Studies 
A1.3.1. Cell Culture 
Breast cancer MCF7 and MDA-MB231 cells (from European Collection of Cell Cultures, ECACC) 
were grown as a monolayer culture in minimum essential medium (DMEM with L-glutamine, without 
glucose and without sodium pyruvate) in the presence of 10% heat-inactivated fetal calf serum, 10 mM 
of D-glucose and 0.1% streptomycin/penicillin in standard culture conditions. 
A1.3.2. Cell Viability Assays 
For these studies, compounds were dissolved in 100% DMSO at 50 mM as stock solution; then, 
serial dilutions have been done in DMSO (1:1) (in this way DMSO concentration in cell media was 
always the same); finally, 1:500 dilutions of the serial dilutions of compounds on cell media were 
done. The assay was performed as described by Givens et al. [82]. In brief, MDA-MB231 and MCF7 
cells were plated at 5,000 cells/well or 10,000 cells/well respectively, in 100 µL media in tissue culture 
96 well plates (Cultek, Boston, USA). After 24 h, media was replaced by 100 µL/well of serial dilution 
of drugs. Each point concentration was run in triplicate. Reagent blanks, containing media plus 
colorimetric reagent without cells were run on each plate. Blank values were subtracted from test 
values and were routinely 5%–10% of uninhibited control values. Plates were incubated for 72 h. 
Hexosamidase activity was measured according to the following protocol: the media containing the 
cells was removed and cells were washed once with PBS 60 µL of substrate solution (p-nitrophenol-N-
acetyl-β-D-glucosamide 7.5 mM (Sigma, San Luis,MO, USA N-9376), sodium citrate 0.1 M, pH = 5.0, 
0.25% Triton X-100 (Sigma-Aldrich Quimica, Tres Cantos, Madrid, Spain), was added to each well 
and incubated at 37 °C for 1–2 h; after this incubation time, a bright yellow color appeared; then, 
plates could be developed by adding 90 µL of developer solution (Glycine 50mM, pH = 10.4; EDTA 5 
mM), and absorbance was recorded at 410 nm. 
A1.4. Electrochemical Studies 
Electrochemical data for compounds under study were obtained by cyclic voltammetry under 
nitrogen at 298 K using acetonitrile (HPLC-grade) as solvent, tetrabutylamonium hexafluorophosphate 
{(Bu4N)[PF6]} (0.1 M) as supporting electrolyte and a M263A potentiostat from EG&G instruments. 
The half-wave potentials were referred to an Ag-AgNO3) 0.1 M in acetonitrile) electrode separated 
from the solution by a medium porosity fritted disk. A platinum wire auxiliary electrode was used in 
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conjunction with a platinum disk working Tacussel-Edi electrode (3.14 mm2). Cyclic voltammograms 
of ferrocene were preformed before and after each sample to ensure the repeatability of the results, in 
particular to test the stability of the Ag-AgNO3 electrode. Cyclic voltammograms of freshly prepared 
solutions (10−3 M) of the samples in acetonitrile were run and potentials measured were the referred to 
the ferrocene that was used as internal internal reference. In these experimental conditions the standard 
error of the measured potentials is ± 5 mV. In all the experiments, the cyclic voltammograms were run 
using scan-speeds (v) in the range: 0.05 V s−1 ≤ v ≤ 1.0 V s−1. 
A1.5. Theoretical Studies 
Calculations were carried out at the B3LYP computational level [70,71] with the Gaussian98  
package [74] using LANL2DZ basis set [72,73]. Geometry optimizations were performed without any 
geometry restriction. 
A2. Summary of Characterization Data for Compounds under Study (Atom Numbering 
Schemes for Compounds 2a, 7a, Diastereomers 8a and 9a, 7b, 8b and 9b Are Presented in 
Figures A1–A6, Respectively) 
A2.1. trans-(SC)-[Pt{κ1-N[FcC(H)=N–CH(Me)(C6H5)]}Cl2(dmso)] (2a) 
Anal. (%) Calc. for C21H25Cl2NOPtS (found): C, 38.14(38.0); H, 3.81(3.75) and N, 2.12(2.02). 
MS(FAB+): m/z = 625.5{[M]-Cl]+. IR: ν (>C=N–) = 1614 cm−1. [α]D (298 K) (c = 0.06 g/100 mL) = 
+386. 1H-NMR data (in CDCl3): δ = 1.99[d, 6H, 3JH,H = 6.8, Me]; 3.40[s, 6H, 3JPt,H = 19, Me(dmso)]; 
4.17(s, 5H, C5H5); 4.56(s,1H, H4); 4.68(s, H, H3); 4.99(s, 1H, H2); 5.46(m, 1H, >CH-), 6.05(s, 1H, H5);  
7.36–7.50 (br.,3H, H3', H4' and H5'); 7.63(d, 1H, 3JH,H = 7.5, H2') and 7.86 (s, 1H, 3JPt,H = 87, –CH=N–). 
1H-NMR data (in CD3CN): δ = 2.02 (d, 6H, Me) [83]; 3.38[s, 6H, 3JPt,H = 18, Me(dmso)]; 4.20(s, 5H, 
C5H5); 4.55(s,1H, H4); 4.66(s, H, H3); 4.70(s, 1H, H5); 5.53(m, 1H, >CH–), 6.15(s, 1H, H2); 7.41–7.54 
(br.,3H, H3', H4' and H5'); 7.70(d, 1H, 3JH,H = 7.5, H2') and 7.88 (s, 1H, 3JPt,H = 86, –CH=N–). 
13C{1H}NMR data (in CDCl3): δ = 20.8 (Me), 43.7 [Me(dmso)], 69.5 (>CH–), 70.1 (C5H5), 71.8 (C2), 
71.5 (C5), 73.6 (C4), 73.8 (C2), 74.3 (C1), 128.9 (C2' and C6'), 128.7(C4'), 129.1(C3' and C5'), 139.8(C1') 
and 169.3(–CH=N–). 195Pt{1H }-NMR data: δ = −2934 ppm. 
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A2.2. (SC)-[Pt{κ2-C,N[(C6H4)CH(Me)–N=C(H)Fc]}Cl(dmso)] (7a) 
Anal. (%) Calc. for C21H24ClFeNOPtS (found): C, 40.36 (40.4); H, 3.87 (3.95), N, 2.24 (2.2)  
and S, 4.85 (4.9). MS(FAB+): m/z = 589.1 {[M]-Cl]+. IR: ν (>C=N–) = 1614 cm−1. [α]D (298 K)  
(c = 0.03 g/100 mL) = +842. 1H-NMR data (in CDCl3): δ = 1.79 (d, 6H, 3JH,H =6.9, Me), 3.61 [s, 3H, 
3JPt–H = 19, Me(dmso)], 3.61[s, 3H, 3JPt–H = 19, Me(dmso)], 4.38 (s, 5H, C5H5), 4.65 (s, 1H, H4), 4.69 
(s, 1H, H3), 4.72 (s, 1H, H2), 4.78(s. 1H, H5), 5.18 (m, 1H, >CH–), 6.90–7.20 (br.m, 3H, H4' H5' H6'), 
8.2 (d, 1H, 3JH,H = 7.5, H3'), and 8.91 (s, 1H, 3JPt–H = 55, –CH=N–). 1H-NMR data (in CD3CN):  
δ = 1.81 (d, 6H, 3JH,H = 7.6, Me), 3.62 (br.s, 6H, Me(dmso)), 4.40 (s, 5H, C5H5), 4.67 (s, 1H, H4),  
4.70 (s, 1H, H3), 4.74 (s, 1H, H2), 4.8 (s. 1H, H5), 5.15 (m, 1H, >CH–), 6.85–7.20 (br.m, 3H, H4' H5' 
H6'), 8.2 (d 1H, 3JH,H = 7.2, H6''), and 8.90 (s, 1H, 3JPt–H = 57, –CH=N–). 13C{1H}-NMR data (in 
CDCl3): δ = 25.6 (Me); 47.2 and 50.4 (Me(dmso)), 70.4 (>CH–); 71.6 (C5H5); 72.8 (C1); 75.2 (C3 and 
C4); 76.4 (C2 and C5); 127.2 (C6'); 126.0 (C3'); 127.2 (C4'); 136.5 (C5'); 156.0 (C2'); and 177.6(–CH=N). 
195Pt{1H}-NMR data: δ = −3610 ppm. 
A2.3. The mixture (II) of the Two Diastereomers of [Pt{{κ2-C,N[(η5-C5H3)–CH=N–{CH(Me)(C6H5)}] 
Fe(η5-C5H5)}Cl(dmso)] (8a and 9a) 
Anal. (%) Calc. for C21H24ClFeNOPtS (found): C, 40.36 (40.25); H, 3.87 (4.0), N, 2.24 (2.30) and 
S, 4.85 (4.67). MS(FAB+): m/z = 587 {[M]-Cl}+. IR: ν (>C=N–) = 1593 cm−1 (broad). 1H-NMR data 
(in CDCl3) for (8a) (minor component): δ = 1.84 (d, 6H, 3JH,H = 6.5, Me), 3.18 (s, 6H, 3JPt,H = 18.4, 
Me(dmso)). 4.36 (s, 5H, C5H5), 4.66 (s, 1H, H3), 4.68 (s, H, H3), 4.80 (s, 1H, H5), 5.42 (m, 1H, >CH–), 
7.15–7.52 (br. m.3H, H3', H4' and H5'), 7.62 (d, 2H, 3JH,H = 7.2, H6') and 8.22 (s, 1H, 3JPt,H = 102, –CH=N–). 
For 9a: (major component): δ = 1.97 (d, 6H, Me), 3.18 (s, 6H, 3JPt,H = 18.5, Me(dmso)),  
4.21 (s, 5H, C5H5), 4.43 (s, 1H, H4), 4.54 (s, H, H3), 4.76 (s, 1H, H5), 5.38 (br.m, 1H, >CH–),  
7.15–7.52 (br. m., 3H, H3', H4' and H5'), 7.7 (d, 2H, 3JH,H = 7.2, H6') and 7.90 (s, 1H, 3JPt,H = 97,  
–CH=N–). 
A2.4. (SC)-[Pt{κ2-C,N[(C6H4)CH(Me)–N=C(H)Fc]}Cl(PPh3)] (7b) 
Anal. (%) Calc. for C37H33ClFeNPPt (found): C, 54.93 (55.05); H, 4.11 (4.15) and N, 1.73 (1.8).  
MS (FAB+): m/z = 808 [M]+ and 772 {[M]-Cl}+. IR: ν (>C=N–) = 1603 cm−1. [α]D (298 K)  
(c = 0.02 g/100 mL) = +896. 
1H-NMR data (in CDCl3): δ = 1.90 (d, 3H, 3JH,H = 7.2, Me), 4.32 (s, 5H, C5H5), 4.57 (s, H, H3), 4.65 
(br, 2H, H2 and H4), 4.78 (br. 1H, H5), 5.36 (m, 1H, >CH–), 6.35 (br.d, 3JH,H ≈ 7.6, 1H, H4'), 6.52(dd, 
1H, 3JH,H = 7.5, 4JP,H = 5.1, H3'), 6.84 (t, 3JH,H = 7.5,1H, H5'), 6.98 (d, 1H, 3JH,H = 7.3, H6'), 7.29–7.90 
(m, 15H, aromatic protons of PPh3) and 9.17 (d, 1H. 3JPt,H = 51.2 and 4JP,H = 77, –CH=N–). 1H-NMR 
data (in CD3CN): δ = 1.94 (d, 3H, 3JH,H = 7.2, Me), 4.32 (s, 5H, C5H5), 4.60 (s, H, H3), 4.65 (br., 2H, 
H2 and H4), 4.81 (br. 1H, H5), 5.40 (m, 1H, >CH–), 6.37 (br.d, 1H, 3JH,H ≈ 7.6, 4JP,H = 6.2, H4'), 6.52(m, 
1H, H3'), 6.84 (br.t, 1H, H5'), 6.98 (d, 1H, H6'), 7.29–7.90 (m, 16H, aromatic prótons of PPh3) and 9.17 
(d, 1H. 3JPt,H = 51.2 and 4JP,H = 8.5, –CH=N–). 13C{1H}-NMR data (in CDCl3): δ = 26.1(Me), 
69.0(C5), 70.5 (C5H5), 70.9 (>CH–), 72.3 (C2), 73.5 (C3), 73.2 (C1); 73.5 (C4), 75.1 (C2); 125.1 (C4'), 
125.3 (C5'), 135.6 (C6'), 138.2 (C1'), 148.1 (C2'), 166.0 (–CH=N–) and four additional doublets centred 
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at 128.0, 130.6; 131.1 and 135.0 due to the carbon-13 nuclei of the PPh3 ligand. 31P{1H}-NMR data:  
δ = 19.1 (1JPt–P= 3801)]. 195Pt{1H}-NMR data δ = −3965 ppm (1JP,Pt = 3800). 
A2.5. Diastereomers of [Pt{κ2-C,N[(η5-C5H3)-CH=N-CH(Me)(C6H5)]Fe(η5-C5H5)}Cl(PPh3)]  
(8b and 9b) 
For 8b: Anal. (%) Calc. for C37H33ClFeNPPt (found): C, 54.93(54.80); H, 4.11(4.15.) and  
N, 1.73 (1.6). MS (FAB+): m/z = 773.5 {[M]-Cl}+. IR: ν (>C=N–) = 1595 cm−1[α]D (298 K)  
(c = 0.04 g/100 mL) = −2016.1H-NMR data for 8b (in CDCl3) δ = 1.85 (d, 3H, 3JH,H = 7, Me), 3.84 (s, 
5H, C5H5), 3.25 (s, H, H3), 4.41 (s, 1H, H4), 4.57 (br. 1H, H5), 6.20 (m, 1H, >CH–), 7.30–7.80 (br.m, 
20H, H2'–H6' and PPh3) and 8.14 (d, 1H. –CH=N–,4JP,H= 8 and 3JPt,H = 90). 1H-NMR data for 8b (in 
CD3CN): δ = 1.92 (d, 3H, 3JH,H = 7, Me), 3.92 (s, 5H, C5H5), 3.35 (s, H, H3), 4.42 (s, 1H, H4), 4.55 (br. 
1H, H5), 6.18 (m, 1H, >CH–), 7.30–7.86 (br.m, 20H, H2'–H6' and PPh3) and 8.15 (d, 1H. –CH=N–,  
4JP,H = 8 and 3JPt,H = 90). 13C{1H}NMR data (in CDCl3): δ = 20.8 (Me), 69.5 (>CH–), 70.1 (C5H5), 
71.8 (C2), 71.5 (C5), 73.6 (C4), 73.8 (C2), 74.3 (C1), 128.9 (C2' and C6'), 128.7 (C4'), 129.1 (C3' and C5'), 
139.8 (C1'), 169.3 (–CH=N–) and four additional doublets centred at ca. 128.0, 130.6; 131.1 and  
135.0 ppm due to the carbon-13 nuclei of the PPh3 ligand. 31P{1H}-NMR data: δ = 15.9 (1JPt,P = 4191). 
195Pt{1H}-NMR data δ = −4176 (1JP,Pt = 4190). 
For 9b: Anal. (%) Calc. for C37H33ClFeNPPt (found): C, 54.93 (54.80); H, 4.11 (4.15.) and N,  
1.73 (1.6). MS (FAB+): m/z = 773.1{[M]-Cl}+. IR: ν(>C=N–) = 1595 cm−1. [α]D (298 K)  
(c = 0.04 g/100 mL) = +1577. 1H-NMR data for 9b (in CDCl3): δ =1.92 (d, 3H, 3JH,H = 7, Me), 3.57 (s, 
5H, C5H5), 3.28 (s, H, H3), 4.55 (s, 1H, H4), 4.61 (br. 1H, H5), 6.40 (m, 1H, >CH-), 7.30–7.80 (br.m, 
20H, H2'–H6' and PPh3) and 8.08 (d, 1H. –CH=N–,4JP,H = 8.0 and 3JPt,H = 94). 1H-NMR data for 9b (in 
CD3CN): δ = 1.99 (d, 3H, 3JH,H = 7, Me) [83] 3.617 (s, 5H, C5H5), 3.40 (s, H, H3), 4.60 (s, 1H, H4), 
4.61 (br. 1H, H5), 6.41 (m, 1H, >CH–), 7.29–7.82 (br.m, 20H, H2'–H6' and PPh3) and 8.10 (d, 1H.  
–CH=N–, 4JP,H = 7.8 and 3JPt,H = 90). 13C{1H}NMR data (in CDCl3): δ = 21.2(Me), 68.5(>CH–), 70.8 
(C5H5),73.6 (C3), 74.8 (C5), 88.16 (C1), 92.2 (C2), 73.8 (C4), 128.6 (C2' and C6'), 128.3 (C4'), 129.1 (C3' 
and C5'), 138.9 (C1'), 180.1 (–CH=N–) and four additional doublets centred at 128.0, 130.6; 131.1 and 
135.0 due to the carbon-13 nuclei of the PPh3 ligand. 31P{1H}-NMR data: δ = 16.2 (1JPt,P = 4202). 
195Pt{1H}-NMR data:δ = −4192 (1JPt,P = 4202). 
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